Amarin Corp Plcuk (AMRN) Current Assets (2010 - 2026)
Amarin Corp Plcuk (AMRN) posted quarterly Current Assets of $626.0 million for Q1 2026, up 9.24% YoY from $573.1 million in Q1 2025, and down 3.67% sequentially from $649.9 million in Q4 2025.
Amarin Corp Plcuk (AMRN) Current Assets (2010 - 2026) Analysis & Trends
Amarin Corp Plcuk has disclosed Current Assets across 17 years of filings, most recently posting $626.0 million for Q1 2026.
- In Q1 2026, Current Assets rose 9.24% year-over-year to $626.0 million; the TTM figure through Mar 2026 stood at $626.0 million (up 9.24% YoY), while the FY2025 annual figure was $649.9 million, up 9.15% from the prior year.
- Current Assets declined to $626.0 million in Q1 2026, from $649.9 million in the prior quarter.
- Over the last five years, Current Assets for AMRN reached as high as $772.6 million in Q1 2022 and fell as low as $573.1 million in Q1 2025.
- The 5-year median for Current Assets is $686.5 million (2022), against an average of $671.7 million.
- Annual changes were most pronounced in 2022 — Current Assets fell 28.71% — and 2026, when it rose 9.24%.
- A 5-year view of Current Assets shows it stood at $689.1 million in 2022, then increased by 5.21% to $725.0 million in 2023, then declined by 17.87% to $595.4 million in 2024, then grew by 9.15% to $649.9 million in 2025, then retreated by 3.67% to $626.0 million in 2026.
- According to Business Quant data, Current Assets over the past three periods registered $626.0 million, $649.9 million, and $628.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 54.84 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 59.17 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 33.53 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | 29.61 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | 35.02 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 31.48 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 18.64 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | 42.82 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Amarin Corp Plcuk | 5.17 Bn | 5.00 Bn | 17.77 Mn | 626.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 626.00 Mn |
| Dec 31, 2025 | 649.88 Mn |
| Sep 30, 2025 | 628.30 Mn |
| Jun 30, 2025 | 606.80 Mn |
| Mar 31, 2025 | 573.06 Mn |
| Dec 31, 2024 | 595.40 Mn |
| Sep 30, 2024 | 650.22 Mn |
| Jun 30, 2024 | 701.80 Mn |
| Mar 31, 2024 | 687.90 Mn |
| Dec 31, 2023 | 724.98 Mn |
| Sep 30, 2023 | 717.51 Mn |
| Jun 30, 2023 | 706.50 Mn |
| Mar 31, 2023 | 683.80 Mn |
| Dec 31, 2022 | 689.10 Mn |
| Sep 30, 2022 | 686.52 Mn |
| Jun 30, 2022 | 719.10 Mn |
| Mar 31, 2022 | 772.62 Mn |
| Dec 31, 2021 | 878.73 Mn |
| Sep 30, 2021 | 963.03 Mn |
| Jun 30, 2021 | 996.00 Mn |